Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second-generation CAR that is outfitted with an ectodoma...

Full description

Bibliographic Details
Main Authors: Endeshaw Chekol Abebe, Mestet Yibeltal Shiferaw, Fitalew Tadele Admasu, Tadesse Asmamaw Dejenie
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
CAR T-cell therapy
cilta-cel
multiple myeloma
efficacy
adverse effects
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.991092/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.991092/full

Similar Items